GlassScriptPhysician profile
Jonathan Ray Baza
NPI 1861840803
$2,753.66
in general payments reported to CMS, 2019-2025
36 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.38 · 2020: $674 · 2021: $605 · 2022: $302 · 2023: $284 · 2024: $374 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $414.99 | 2020-2025 | Vraylar |
| Pfizer INC. | $241.60 | 2020-2025 | |
| Amgen INC. | $218.03 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $162.84 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Boston Scientific Corporation | $157.17 | 2020-2025 | Watchman Access System, General - Pain Management |
| Novo Nordisk INC | $156.83 | 2020-2024 | Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.17 | 2020-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $131.04 | 2020-2024 | Spravato |
| Merck Sharp & Dohme LLC | $101.43 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $77.87 | 2019-2021 | |
| Ibsa Pharma INC. | $77.08 | 2020-2025 | Licart, Flector, Tirosint |
| Lilly USA, LLC | $74.77 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Biohaven Pharmaceuticals, INC. | $71.65 | 2021 | |
| Allergan, INC. | $71.07 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.39 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $50.69 | 2025 | Inspire |
| Lucid Diagnostics INC. | $49.74 | 2023 | |
| Organon LLC | $49.09 | 2025 | Nexplanon |
| Neurocrine Biosciences, INC. | $45.23 | 2020 | |
| Medtronic, INC. | $44.49 | 2022-2025 | Minimed 780g, Venaseal |
| Nevro Corp. | $41.51 | 2022 | |
| Strongbridge US INC. | $37.46 | 2019-2020 | |
| Daiichi Sankyo INC. | $34.62 | 2020-2024 | Injectafer |
| Amarin Pharma, INC. | $34.57 | 2020-2021 | |
| Abbott Laboratories | $22.77 | 2024 | Eterna |
| Ani Pharmaceuticals, INC. | $20.80 | 2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $20.78 | 2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $20.67 | 2020 | |
| Grifols USA, LLC | $20.22 | 2025 | Prolastin-C Liquid |
| Alfasigma USA, INC. | $18.87 | 2021 | |
| Exact Sciences Corporation | $18.00 | 2023 | Cologuard Collection Kit |
| Halozyme INC | $16.86 | 2023 | |
| Glaxosmithkline, LLC. | $16.85 | 2024 | Shingrix |
| Xeris Pharmaceuticals, INC. | $15.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.67 | 2022 | |
| Sumitomo Pharma America, INC. | $12.15 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Baza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.